Thyro-Tabs

Verify with FDA CVM →

37 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
37
Total Reports
3
Deaths Reported
810.0%
Death Rate

Active Ingredients

Thyro-Tabs

Administration Routes

OralUnknown

Species Affected

Dog 36
Cat 1

Most Affected Breeds

Retriever - Labrador 6
Retriever - Golden 4
Doberman Pinscher 4
Crossbred Canine/dog 3
Beagle 3
Shepherd Dog - German 3
Terrier - Bull - American Pit 2
Greyhound 2
Portuguese Water Dog 1
Terrier - Boston 1

Most Reported Reactions

Falling 5
Polydipsia 4
Anaemia NOS 4
Polyuria 3
Lethargy (see also Central nervous system depression in 'Neurological') 3
Ataxia 3
Hiding 3
Elevated alanine aminotransferase (ALT) 3
Lethargy (see also Central nervous system depression in Neurological) 3
Cough 3
Urinary tract infection 3
Elevated globulins 3

Outcome Breakdown

Ongoing
23 (62.2%)
Outcome Unknown
9 (24.3%)
Recovered/Normal
2 (5.4%)
Euthanized
2 (5.4%)
Died
1 (2.7%)

Data Summary

Metric Value
Total adverse event reports 37
Reports involving death 3
Case-fatality rate (reported events) 810.0%
Distinct species in reports 2
Distinct breeds in reports 18
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Thyro-Tabs Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 37 adverse event reports referencing Thyro-Tabs, including 3 reports in which the animal died — a 810.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Thyro-Tabs. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Thyro-Tabs reports are Dog (36 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (6), Retriever - Golden (4), Doberman Pinscher (4) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Thyro-Tabs are Falling (5), Polydipsia (4), Anaemia NOS (4), Polyuria (3). Of the 37 reports with a coded outcome, Ongoing is the leading category at 62.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Thyro-Tabs.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial